MARIETTA, Ga., March 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today it will be hosting a webcast on Thursday, March 9, 2017 beginning at 10:30 a.m. Eastern Time to discuss numerous strategic and tactical initiatives that the Company has undertaken, as well as provide more in-depth information on other key topics requested by shareholders.
The Company reported that "Pete" Petit, Chairman and CEO; Bill Taylor, President and COO; Chris Cashman, EVP and Chief Commercialization Officer; Debbie Dean, Executive Vice President; Brent Miller, Executive Vice President; and Mark Landy, Vice President, will be presenting during the March 9 call. Also present will be Donald Fetterolf, M.D., Chief Medical Officer; Thomas Koob, PhD, Chief Scientific Officer; and other members of MiMedx senior management.
The Company expects the planned presentations to last approximately 50 minutes. After the planned presentations, the call will be open for questions and answers. The subject matter, topics and updates to be covered during the formal presentations include:
- Company's FDA Regulatory Plans
- Competitive Landscape
- Patent and Intellectual Property Matters
- Clinical and Scientific Studies
- National Reimbursement Progress
- Scientific Insights Into New Products
- Company Market Valuations
Parker H. "Pete" Petit, Chairman and CEO stated, "We will discuss our initiatives for a new strategic positioning of the Company, which aligns with the substantial asset base we have built over the last four years. Please join us for this timely update."
A listen-only simulcast of the MiMedx Group March 9, 2017 shareholder call and presentation slides will be available on-line at the Company's website at www.mimedx.com. beginning at 10:30 a.m. eastern time, March 9, 2017. A 30-day on-line replay will be available approximately one hour following the conclusion of the live broadcast on the Company's website at www.mimedx.com.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the new strategic initiatives and their alignment with the substantial asset base of the Company. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the new initiatives do not align with the substantial asset base as expected, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2016, and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-host-shareholder-call-on-march-9-2017-to-present-various-strategic-and-tactical-initiatives-to-shareholders-300416606.html
SOURCE MiMedx Group, Inc.